181 related articles for article (PubMed ID: 26319063)
1. Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.
Troy JD; Hill HR; Ewell MG; Frey SE
Vaccine; 2015 Oct; 33(41):5425-5431. PubMed ID: 26319063
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Frey SE; Winokur PL; Salata RA; El-Kamary SS; Turley CB; Walter EB; Hay CM; Newman FK; Hill HR; Zhang Y; Chaplin P; Tary-Lehmann M; Belshe RB
Vaccine; 2013 Jun; 31(29):3025-33. PubMed ID: 23664987
[TBL] [Abstract][Full Text] [Related]
3. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.
Frey SE; Winokur PL; Hill H; Goll JB; Chaplin P; Belshe RB
Vaccine; 2014 May; 32(23):2732-9. PubMed ID: 24607004
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
von Krempelhuber A; Vollmar J; Pokorny R; Rapp P; Wulff N; Petzold B; Handley A; Mateo L; Siersbol H; Kollaritsch H; Chaplin P
Vaccine; 2010 Feb; 28(5):1209-16. PubMed ID: 19944151
[TBL] [Abstract][Full Text] [Related]
5. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P; Keitel W; Hill H; Goll JB; Anderson EL; Graham IL; Johnston C; Mulligan M; Rouphael N; Atmar R; Patel S; Chen W; Kotloff K; Creech CB; Chaplin P; Belshe RB
Vaccine; 2015 Sep; 33(39):5225-34. PubMed ID: 26143613
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.
Garza NL; Hatkin JM; Livingston V; Nichols DK; Chaplin PJ; Volkmann A; Fisher D; Nalca A
Vaccine; 2009 Sep; 27(40):5496-504. PubMed ID: 19632316
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
[TBL] [Abstract][Full Text] [Related]
10. Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits.
Tree JA; Hall G; Rees P; Vipond J; Funnell SG; Roberts AD
Hum Vaccin Immunother; 2016 Jul; 12(7):1795-801. PubMed ID: 26836234
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
Frey SE; Newman FK; Kennedy JS; Sobek V; Ennis FA; Hill H; Yan LK; Chaplin P; Vollmar J; Chaitman BR; Belshe RB
Vaccine; 2007 Dec; 25(51):8562-73. PubMed ID: 18036708
[TBL] [Abstract][Full Text] [Related]
12. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.
Kennedy JS; Greenberg RN
Expert Rev Vaccines; 2009 Jan; 8(1):13-24. PubMed ID: 19093767
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
15. Clinical guidance for smallpox vaccine use in a postevent vaccination program.
Petersen BW; Damon IK; Pertowski CA; Meaney-Delman D; Guarnizo JT; Beigi RH; Edwards KM; Fisher MC; Frey SE; Lynfield R; Willoughby RE
MMWR Recomm Rep; 2015 Feb; 64(RR-02):1-26. PubMed ID: 25695372
[TBL] [Abstract][Full Text] [Related]
16. Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations.
Slike BM; Creegan M; Marovich M; Ngauy V
PLoS One; 2017; 12(1):e0169247. PubMed ID: 28046039
[TBL] [Abstract][Full Text] [Related]
17. Antibodies Induced by Smallpox Vaccination after at Least 45 Years Cross-React with and In Vitro Neutralize Mpox Virus: A Role for Polyclonal B Cell Activation?
Mariotti S; Venturi G; Chiantore MV; Teloni R; De Santis R; Amendola A; Fortuna C; Marsili G; Grilli G; Lia MS; Kiros ST; Lagi F; Bartoloni A; Iacobino A; Cresta R; Lastilla M; Biselli R; Di Bonito P; Lista F; Nisini R
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675961
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
19. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
von Sonnenburg F; Perona P; Darsow U; Ring J; von Krempelhuber A; Vollmar J; Roesch S; Baedeker N; Kollaritsch H; Chaplin P
Vaccine; 2014 Sep; 32(43):5696-702. PubMed ID: 25149431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
